A Phase Ib/IIa Single-Arm, Open-Label Clinical Trial to Evaluate the Safety, Pharmacokinetics, and Efficacy of BP1001 (A Liposomal Grb2 Antisense Oligonucleotide) In Combination with Dasatinib (Das) In Patients with Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) In Accelerated or Blast Phase, Ph+ Acute Myeloid Leukemia (AML) or High-risk Ph+ Myelodysplastic Syndrome (MDS)
MD Anderson Study Status
BP1001 (varying dose), BP1001 (fixed dose), Dasatinib
The primary objective of the Phase Ib study is to determine the dose-limiting toxicity (DLT) and maximal tolerated dose (MTD) of BP1001 in combination with dasatinib in patients with with Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) including chronic phase patients who have failed initial tyrosine kinase inhibitor (TKI) therapy, accelerated or blast phase, Ph+ Acute Myeloid Leukemia (AML) or High-risk Ph+ Myelodysplastic Syndrome (MDS). The primary objective of the Phase IIa study is to assess the efficacy of the combination of BP1001 and dasatinib in patients with Ph+ CML, Ph+AML, or high-risk Ph+ MDS.
Information and next steps
Chronic Myelogenous Leukemia, Ph1-Positive, Acute Myeloid Leukemia, Myelodysplastic Syndrome
For general questions about clinical trials: